Ionizable drug delivery systems for efficient and selective gene therapy

Mil Med Res. 2023 Feb 27;10(1):9. doi: 10.1186/s40779-023-00445-z.

Abstract

Gene therapy has shown great potential to treat various diseases by repairing the abnormal gene function. However, a great challenge in bringing the nucleic acid formulations to the market is the safe and effective delivery to the specific tissues and cells. To be excited, the development of ionizable drug delivery systems (IDDSs) has promoted a great breakthrough as evidenced by the approval of the BNT162b2 vaccine for prevention of coronavirus disease 2019 (COVID-19) in 2021. Compared with conventional cationic gene vectors, IDDSs can decrease the toxicity of carriers to cell membranes, and increase cellular uptake and endosomal escape of nucleic acids by their unique pH-responsive structures. Despite the progress, there remain necessary requirements for designing more efficient IDDSs for precise gene therapy. Herein, we systematically classify the IDDSs and summarize the characteristics and advantages of IDDSs in order to explore the underlying design mechanisms. The delivery mechanisms and therapeutic applications of IDDSs are comprehensively reviewed for the delivery of pDNA and four kinds of RNA. In particular, organ selecting considerations and high-throughput screening are highlighted to explore efficiently multifunctional ionizable nanomaterials with superior gene delivery capacity. We anticipate providing references for researchers to rationally design more efficient and accurate targeted gene delivery systems in the future, and indicate ideas for developing next generation gene vectors.

Keywords: Gene therapy; Ionizable drug delivery systems (IDDSs); Ionizable nanomaterials; Nucleic acids.

Publication types

  • Review

MeSH terms

  • BNT162 Vaccine
  • COVID-19* / therapy
  • Drug Delivery Systems
  • Genetic Therapy
  • Humans
  • Nucleic Acids*

Substances

  • BNT162 Vaccine
  • Nucleic Acids